Embed Size (px)
Citation preview
Precision cryosystems for precise medicines
Lisbon, March16th 2017
PROBLEM
Lack of Effective Cryopreservation Tools to make Cell and Protein based therapies viable and available for everybody.
TRACTIONSmartFreez has been requested by a few of the Top 10 Pharma Players, and has been generating revenues in the last 18 months:
1.2.3.4.5.6.7.8.9.10.
Designing and providing cryopreservation systems:
Watch the vídeo at: http://smartfreez.com/solutions/computational-fluid-dynamics/
SOLUTIONProblems: Solutions:
Cell low survival rate
Use of toxic cryopreservatives (DMSO)
Unstandardized freeze-thawing procedures
Cryopreservation method design
Inconsistent freezing
Cells
Prot
eins
SmartCryo - Cells 1 (for the Lab & Research
Market)
SmartCryo - Cold Stability Accelerator
SmartCryo - Cube (small and large
scale)
SmartCryo - Cells 2 (Medical Device)
US made Cryocube unit complying with pharma
industry standards
Protein Stability Study tool to replicate in a few weeks the freezing pattern of years!
Better performance on cell cryopreservation vs the major competitor
MARKET & COMPETITIONMarket Competition
Biopreservation Global Market – a strong and fast growing sector!
2015 2024 CAGR
$3Bn $9.7Bn 13.4%
Cell Cryopreservation
Protein Cryopreservation
Safe
ty SmartCryo Cells
Quality- + Quality- +
SmartCryo Cube
Bio-cision
Asymp-tote
Zeta
Sarto-rius
+
TEAMMiguel Rodrigues – PhD, CEO
– Expert in Pharmaceutical Engineering – thermodynamics and cryogenic technologies.
– More than 10 years of experience enhancing stability and delivery of pharmaceutical substances.
Vitor Geraldes – PhD, CTO
– Expert in process engineering, transport phenomena and computational methods.
– More than 15 years of experience modelling and developing systems for food and medical industry
Rui Estrela – MBA, COO
– Expertise in Marketing, Financial Controlling and Business Development
– More than 15 years of experience national and multi-national companies (BDO Binder, F. Lima, Reckitt Benckiser).
Pedro Rego – MSc, Research Engineer
– Specialised on CFD, cryopreservation of unicelular organisms and experimental scientific projects.
– Expert in experimental models and prototyping for low temperatures.
Andreia Duarte – PhD, Research Scientist
– Graduation in Biochemistry and PhD in Biomedicine.
– Experience in protein aggregation studies, microbiology and cell related research.
BUSINESS MODELKEY ACTIVITIES
• Technology and Quality Control
• New Product Development
KEY ACTIVITIES
• Manufacturing partners
• Distribution partners
KEY PARTNERS
• R&D
• Engineering
KEY RESOURCES
KEY ACTIVITIES
• Biopharma & biotech companies
• Hospitals & clinical treatment centers
CUSTOMER SEGMENTS
• Global Distributors
CHANNELS
• Equipment sales revenues
REVENUE MODEL
GOALS & MILESTONESNext 15 Months:
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
* Expand IP/Patent Protection
*Finalize Cold Stability Accelerator & SmartCryo Cells pilot equipment (complying with standards)
*Pilot testing of SmartCryo Cube in a relevant biopharma player and publishing of results
* Pilot testing of Cold Stability Accelerator & SmartCryo Cells with relevant players
* Global Launch of SmartCryo Cube
* Global launch of Cold Stability Accelerator & SmartCryo Cells (in lab & research market)
BUSINESS MODEL
1. Miguel Rodrigues2. Vitor Geraldes3. Rui Estrela
The original founders still own 100% of SmartFreez’s equity
Equity Owners:
FUND RAISING & USE OF PROCEEDSTotal Funds Needed: 2M€
Use of Proceeds:
1. Product Development: 550 K€2. Patent Protection and Legal: 250 K€3. Regulatory Diligences: 500 K€4. Marketing/Scaling: 480 K€5. Working Capital: 220 K€TOTAL 2 000 K€
EXIT STRATEGY
Potential Buyers:
Sale of Business Areas:
2022
Cold Stability Accelerator SmartCryo - Cube
Analytical Equipment Playerex: HP Agilent
Industrial Systems Playerex: Sartorius, Pall Corporation
SmartCryo - Cells
2027
Medical Technology Player ex: GE Healthcare, Medtronic
